# BioRepository for INvestigation of Diseases of the Lung  (BRINDL) - Phase III

> **NIH NIH U01** · UNIVERSITY OF ROCHESTER · 2024 · $462,000

## Abstract

ABSTRACT
Respiratory tract disease is surpassed only by mental health as the top-most costly and frequent medical
condition affecting our children and resulting in adult disease with perinatal-pediatric origins. "The overall
goal of LungMAP is to build a comprehensive molecular and cellular atlas of the human lung to serve as a
reference platform to better understand both normal biology and disease pathobiology, and to identify
critical cellular components, molecular pathways, and novel therapeutic targets in lung disease." Discovery
of meaningful treatments for these disorders is limited by the rarity of access to sufficient normal and
diseased human lung for high resolution, multi-scale study. Having, as the original Human Tissue Core
(HTC) for the Molecular Atlas of Lung Development Program (LungMAP), created the BioRepository for
INvestigation of Diseases of the Lung (BRINDL), encouraged and facilitated use of these biospecimens in
highly productive collaborations between LungMAP HTC and RCs, developed new techniques for preserving
and assaying these high-quality human tissues, and distributed biospecimens to the research community,
the University of Rochester Medical Center (URMC) submits this renewal application in response to single
source RFA-HL-24-015 to continue to serve as the HTC for LungMAP Phase 3. Begun as a repository for
normal pediatric development, LungMAP II extended to include pediatric rare diseases including
bronchopulmonary dysplasia, chILD, pulmonary hypoplasia and the more common disease, asthma. In
Phase III, our proposal closely follows the Notice of Funding Opportunity that summarizes the "main goal of
the HTC in Phase 3 is to catalog, store, and distribute human lung samples from the current LungMAP
repository and from the LungMAP Research Centers (RCs)." The HTC will, while complying with current
NIH and regulatory policies, selectively add pediatric rare lung diseases and certain healthy pediatric
cases, enhance diversity in ethnicity and ancestry, assist Research Centers in acquiring diseases of their
expertise, organize all case metadata within BRINDL, improve the BRINDL specimen and data
management and distribution system (https://brindl.urmc.rochester.edu), integrate with the DCC portal
system to improve user experience, and prepare to transition the biorepository at LungMAP sunset.

## Key facts

- **NIH application ID:** 10975581
- **Project number:** 2U01HL148861-06
- **Recipient organization:** UNIVERSITY OF ROCHESTER
- **Principal Investigator:** GLORIA S PRYHUBER
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $462,000
- **Award type:** 2
- **Project period:** 2019-08-23 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10975581

## Citation

> US National Institutes of Health, RePORTER application 10975581, BioRepository for INvestigation of Diseases of the Lung  (BRINDL) - Phase III (2U01HL148861-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10975581. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*